{"id":"NCT02585934","sponsor":"Axovant Sciences Ltd.","briefTitle":"Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study","officialTitle":"A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2017-09","completion":"2017-09","firstPosted":"2015-10-26","resultsPosted":"2018-12-05","lastUpdate":"2018-12-05"},"enrollment":1315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"RVT-101","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RVT-101","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.","primaryOutcome":{"measure":"Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24","timeFrame":"Baseline, 24 weeks","effectByArm":[{"arm":"RVT-101","deltaMin":0.39,"sd":0.211},{"arm":"Placebo","deltaMin":0.75,"sd":0.213}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2249"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":197,"countries":["United States","Argentina","Australia","Bulgaria","Canada","Chile","Croatia","Czechia","France","Germany","Italy","Poland","Serbia","Singapore","Slovakia","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":656},"commonTop":["Fall","Urinary tract infection","Nasopharyngitis","Headache","Dizziness"]}}